MedTrace Logo

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

NCT03923270 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-04-01

No results posted yet for this study

Summary

This is a randomized multi-arm trial evaluating the safety and efficacy of thoracic radiation therapy followed by either durvalumab as monotherapy or in combination with tremelimumab or olaparib in participants with Extensive-Stage Disease Small Cell Lung Cancer (ES-SCLC) who have completed a first-line platinum-based chemotherapy regimen and achieved ongoing complete response (CR), partial response (PR) or stable disease (SD).

Conditions

  • Small Cell Lung Cancer Extensive Stage
  • Small-cell Lung Cancer

Interventions

DRUG

Durvalumab

Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.

DRUG

Tremelimumab

Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.

DRUG

Olaparib Pill

Participants in arm C will be self-administer 300 mg of Olaparib orally.

RADIATION

Thoracic Radiotherapy

Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions

DRUG

Tremelimumab

Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Alberto A Chiappori, MD · H. Lee Moffitt Cancer Center and Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-06
Primary Completion
2023-06-01
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923270 on ClinicalTrials.gov